Literature DB >> 34155394

Benefit with adjuvant metronomic capecitabine in NPC.

Diana Romero1.   

Abstract

Entities:  

Year:  2021        PMID： 34155394     DOI： 10.1038/s41571-021-00536-7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Authors:  Yu-Pei Chen; Xu Liu; Qin Zhou; Kun-Yu Yang; Feng Jin; Xiao-Dong Zhu; Mei Shi; Guo-Qing Hu; Wei-Han Hu; Yan Sun; Hong-Fen Wu; Hui Wu; Qin Lin; Hui Wang; Ye Tian; Ning Zhang; Xi-Cheng Wang; Liang-Fang Shen; Zheng-Zheng Liu; Jing Huang; Xiu-Ling Luo; Ling Li; Jian Zang; Qi Mei; Bao-Min Zheng; Dan Yue; Jing Xu; San-Gang Wu; Yan-Xia Shi; Yan-Ping Mao; Lei Chen; Wen-Fei Li; Guan-Qun Zhou; Rui Sun; Rui Guo; Yuan Zhang; Cheng Xu; Jia-Wei Lv; Ying Guo; Hui-Xia Feng; Ling-Long Tang; Fang-Yun Xie; Ying Sun; Jun Ma
Journal:  Lancet       Date:  2021-06-07       Impact factor: 202.731
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.